Cyramza and Tarceva combination therapy first-line treatment NSCLC critical Phase 3 trial yielded positive results

recently, Lilly announced that its anti-vascularly generated mono-anti-
drug(http://Cyramza (ramucirumab) and Roche's tyrosine kinase inhibitor Tarceva (erlotinib, erlotinib) combined the rapto therapy, in the first-line treatment of patients with eGFR gene mutation stonal metastatic non-small cell lung cancer (NSCLC) patients with a critical phase 3trial (http://positive resultsAbout CyramzaVascular Endothelial Growth Factor (VEGF) receptor 2 antagonist Cyramza, an antiangiogenic therapyCyramza blocks the activation of this signaling pathway by blocking the specific binding of VEGF receptor s2 and VEGF-A, VEGF-C and VEGF-DBlocking the connection of veGF proteins to blood vessels helps to inhibit tumor growth by slowing bloodsupply of(http://Cyramza has been approved by theFDA(http://as a 2-line therapy for gastric, NSCLC, colorectal cancer, and hepatocellular carcinoma (HCC)In the study
449 patients with eGFR gene mutations (exoskeleton 19 missing or exogenous 21 L858R replacement mutations) were involved in phase 3 trial RELAY, and were randomized to receive a combination of Cyramza and Ellotinib, or placebo and ellotinib 　　Compared to PFS in the Elotini group of 12.4 months, the PFS in the combination therapy group was 19.4 months, reaching the main endpoint of the trial of significantly prolonged PFS 　　The combination therapy group improved in terms of mitigation duration, second progression or time of death (PFS2), and secondary or exploratory endpoints such as time for targeted treatment (time on targeted therapy)